The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans

European Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2013, Pages 21-30

  Suzaki, Yuki ^a   Uemura, Naoto ^b   Takada, Makoto ^c   Ohyama, Tetsuji ^a,b   Itohda, Akiko ^b   Morimoto, Takuya ^a   Imai, Hiromitsu ^a,b   Hamasaki, Hajime ^a,b   Inano, Akihiro ^d   Hosokawa, Masakiyo ^e   Tateishi, Masato ^c   Ohashi, Kyoichi ^a,b  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

^c NAGASAKI INTERNATIONAL UNIVERSITY   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e CHIBA INSTITUTE OF SCIENCE   (Japan)

Author keywords

Carboxylesterase; CES1; Genetic polymorphism; Oseltamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CARBOXYLESTERASE; CARBOXYLESTERASE 1; OSELTAMIVIR; UNCLASSIFIED DRUG;

ABNORMAL BEHAVIOR; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CES1 GENE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE DOSAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TIME OF FLIGHT MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOXYLIC ESTER HYDROLASES; FEMALE; GENOTYPE; HUMANS; MALE; OSELTAMIVIR; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84872331283     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1315-5     Document Type: Article

References (26)

1. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW et al (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363(6428):418-423. doi: 10.1038/363418a0
2. Bardsley-Elliot A, Noble S (1999) Oseltamivir. Drugs 58(5):851-860, discussion 861-852
3. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319(3):1477-1484. doi: 10.1124/jpet.106.111807
4. Satoh T, Hosokawa M (2006) Structure, function and regulation of carboxylesterases. Chem Biol Interact 162(3):195-211. doi: 10.1016/j.cbi.2006. 07.001
5. Hosokawa M (2008) Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13(2):412-431
6. Redinbo MR, Potter PM (2005) Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov Today 10(5):313-325. doi: 10.1016/S1359-6446(05)03383-0
7. Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21(3):173-185
8. Imai T, Taketani M, Shii M, Hosokawa M, Chiba K (2006) Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 34(10):1734-1741. doi: 10.1124/dmd.106.009381
9. Hosokawa M, Furihata T, Yaginuma Y, Yamamoto N, Watanabe N, Tsukada E, Ohhata Y, Kobayashi K, Satoh T, Chiba K (2008) Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metab Pharmacokinet 23(1):73-84
10. Tanimoto K, Kaneyasu M, Shimokuni T, Hiyama K, Nishiyama M (2007) Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet Genomics 17(1):1-10. doi: 10.1097/01.fpc.0000230110.18957.50
11. Fukami T, Nakajima M, Maruichi T, Takahashi S, Takamiya M, Aoki Y, McLeod HL, Yokoi T (2008) Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics 18(10):911-920. doi: 10.1097/FPC.0b013e32830b0c5e
12. Izumi Y, Tokuda K, O'Dell KA, Zorumski CF, Narahashi T (2007) Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 426(1):54-58. doi: 10.1016/j.neulet.2007.08.054
13. Sai K, Saito Y, Tatewaki N, Hosokawa M, Kaniwa N, Nishimaki-Mogami T, Naito M, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Tamura T, Yamada Y, Ohe Y, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Okuda H (2010) Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br J Clin Pharmacol 70(2):222-233. doi: 10.1111/j.1365-2125.2010.03695.x
14. Heinig K, Bucheli F (2008) Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 876(1):129-136. doi: 10.1016/j.jchromb.2008.10.037
15. Holmes RS, Wright MW, Laulederkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M, Perkins EJ, Potter PM, Redinbo MR, Robert J, Satoh T, Yamashita T, Yan B, Yokoi T, Zechner R, Maltais LJ (2010) Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome 21(9-10):427-441. doi: 10.1007/s00335-010-9284-4
16. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, Saito T, Koga A, Muramatsu M, Katagiri T (2005) A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertens Res 28(9):719-725. doi: 10.1291/hypres.28.719
17. He G, Massarella J, Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37(6):471-484
18. Ogihara T, Kano T, Wagatsuma T, Wada S, Yabuuchi H, Enomoto S, Morimoto K, Shirasaka Y, Kobayashi S, Tamai I (2009) Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos 37(8):1676-1681. doi: 10.1124/dmd.109.026922
19. Snell P, Dave N, Wilson K, Rowell L, Weil A, Galitz L, Robson R (2005) Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol 59(5):598-601. doi: 10.1111/j.1365-2125.2005.02340.x
20. Schwarz R, Kaspar A, Seelig J, Kunnecke B (2002) Gastrointestinal transit times in mice and humans measured with 27Al and 19 F nuclear magnetic resonance. Magn Reson Med 48(2):255-261. doi: 10.1002/mrm.10207
21. Morimoto K, Kishimura K, Nagami T, Kodama N, Ogama Y, Yokoyama M, Toda S, Chiyoda T, Shimada R, Inano A, Kano T, Tamai I, Ogihara T (2011) Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. J Pharm Sci 100(9):3854-3861. doi: 10.1002/jps.22627
22. Anderle P, Nielsen CU, Pinsonneault J, Krog PL, Brodin B, Sadee W (2006) Genetic variants of the human dipeptide transporter PEPT1. J Pharmacol Exp Ther 316(2):636-646. doi: 10.1124/jpet.105.094615
23. Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I, Ogihara T (2008) Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos 36(1):6-9. doi: 10.1124/dmd.107.017699
24. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y (2009) Limited brain distribution of [3R,4R,5 S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxyl ate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 37(2):315-321. doi: 10.1124/dmd.108.024018
25. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473-3478. doi: 10.1073/pnas.050585397
26. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL (2008) The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 325(3):859-868. doi: 10.1124/jpet.108. 136523